Kura Oncology (NASDAQ:KURA) Hits New 52-Week Low – What’s Next?

Kura Oncology, Inc. (NASDAQ:KURA)’s stock price hit a new 52-week low during trading on Tuesday . The company traded as low as $8.34 and last traded at $8.56, with a volume of 96391 shares traded. The stock had previously closed at $8.51.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. Wedbush reissued an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a report on Monday, November 4th. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a report on Tuesday, November 19th. UBS Group began coverage on Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective on the stock. Finally, TD Cowen restated a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $27.38.

Kura Oncology Stock Down 4.8 %

The stock has a market cap of $605.00 million, a price-to-earnings ratio of -3.30 and a beta of 0.81. The firm has a 50 day simple moving average of $12.11 and a two-hundred day simple moving average of $17.08. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Institutional Investors Weigh In On Kura Oncology

Several large investors have recently bought and sold shares of the company. Suvretta Capital Management LLC grew its holdings in shares of Kura Oncology by 8.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after buying an additional 583,155 shares during the period. Armistice Capital LLC lifted its holdings in Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after acquiring an additional 302,000 shares in the last quarter. Geode Capital Management LLC grew its stake in Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock valued at $34,798,000 after acquiring an additional 41,535 shares during the period. Franklin Resources Inc. increased its holdings in shares of Kura Oncology by 1.5% in the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock worth $28,687,000 after acquiring an additional 23,113 shares in the last quarter. Finally, Sofinnova Investments Inc. raised its position in shares of Kura Oncology by 64.4% during the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock worth $16,992,000 after purchasing an additional 323,303 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.